Mycobacterium avium genotype is associated with the therapeutic response to lung infection  by Kikuchi, T. et al.
Mycobacterium avium genotype is associated with the therapeutic
response to lung infection
T. Kikuchi1,2, Y. Kobashi3, T. Hirano1, N. Tode1, A. Santoso1, T. Tamada2, S. Fujimura4, Y. Mitsuhashi1, Y. Honda1, T. Nukiwa1,
M. Kaku5, A. Watanabe4 and M. Ichinose1,2
1) Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 2) Department of Respiratory Medicine, Tohoku University Hospital,
Sendai, 3) Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Kurashiki, 4) Department of Aging and Cancer, Research Division
for Development of Anti-Infective Agents, Institute of Development, Tohoku University and 5) Department of Infection Control and Laboratory Diagnostics,
Tohoku University Graduate School of Medicine, Sendai, Japan
Abstract
Factors that can interfere with the successful treatment of Mycobacterium avium lung infection have been inadequately studied. To identify a
potent predictor of therapeutic responses of M. avium lung infection, we analyzed variable number tandem repeats (VNTR) at 16
minisatellite loci ofM. avium clinical isolates. Associations between the VNTR proﬁling data and a therapeutic response were evaluated in 59
subjects with M. avium lung infection. M. avium lung infection of 30 subjects in whom clarithromycin-containing regimens produced
microbiological and radiographic improvement was deﬁned as responsive disease, while that of the remaining 29 subjects was deﬁned as
refractory disease. In phylogenetic analysis using the genotypic distance aggregated from 16-dimensional VNTR data, 59 M. avium isolates
were divided into three clusters, which showed a nearly signiﬁcant association with therapeutic responses (p 0.06). We then subjected the
raw 16-dimensional VNTR data directly to principal component analysis, and identiﬁed the genetic features that were signiﬁcantly associated
with the therapeutic response (p <0.05). By further analysis of logistic regression with a stepwise variable-selection, we constructed the
highest likelihood multivariate model, adjusted for age, to predict a therapeutic response, using VNTR data from only four minisatellite loci.
In conclusion, we identiﬁed four mycobacterial minisatellite loci that together were associated with the therapeutic response of M. avium
lung infections.
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Introduction
Mycobacterium avium is the pathogen that accounts for most
cases of non-tuberculous mycobacterial lung infection, and an
increase in its prevalence worldwide has been noted [1–5]. In
the treatment of M. avium lung infections, aggressive macro-
lide-based multidrug therapy for 12–24 months is recom-
mended [1,2,5]. However, the lack of factors predictive of the
therapeutic response, with the exception of macrolide resis-
tance predicting treatment failure, often discourages clinicians
from starting the long-term, aggressive therapy required
[1,2,5,6]. This is particularly problematic when the symptoms
of the patient are so moderate that treatment-related adverse
effects may be worse than the lung disease itself [2,7].
Methods for molecular typing of mycobacteria have been
developed, especially for investigation of Mycobacterium tuber-
culosis epidemiology [2,8,9]. Among them, evaluation of
variable number tandem repeats (VNTR) by polymerase chain
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reaction (PCR) has received particular attention, due to both
its discriminatory ability and its convenience [10,11]. Its
discriminatory power depends on the number of evaluated
minisatellite loci, of which 12–24 have been evaluated for
mycobacterial typing [10]. Each mycobacterial isolate is
proﬁled as a set of 12–24 integer values that correspond to
the numbers of repeats at the evaluated minisatellite loci. To
date, the raw digital data of the VNTR proﬁles have been
analyzed after analog interpretation in a phylogenetic tree
[9,12,13]. In the present study, our ﬁndings demonstrate that
the 16-digit VNTR data, and particularly those from the four
selected minisatellite loci, may be directly analyzed, without
the digital-to-analog conversion required for phylogenetic
analysis, for use as predictors of the therapeutic response in
M. avium lung infection.
Material and Methods
Study population
Our analysis included 59 subjects who were diagnosed with
M. avium lung infection according to the ofﬁcial American
Thoracic Society/Infectious Diseases Society of America (ATS/
IDSA) statement, and were treated with clarithromycin-based
multidrug regimens at the Tohoku University Hospital or at
the Kawasaki Medical School Hospital [2]. Patients who had
completed at least 6 months of therapy were chosen for this
study. Among them, 17 subjects from the Tohoku University
Hospital had been included in a previous unrelated study [13].
Therapeutic response was evaluated 6 months after the start
of medication, based on microbiological and radiographic
ﬁndings. Microbiological improvement was determined as
sputum culture negativity for 3 months at 4–6 months after
the start of treatment; radiographic regression after 6 months
of treatment was determined on the basis of standards
described previously [14]. Subjects who met both microbio-
logical and radiographic criteria were classiﬁed as having
responsive M. avium lung disease, while those whose results
failed to meet either of the criteria were classiﬁed as having
refractory disease. The Institutional Review Board at Tohoku
University Graduate School of Medicine (Sendai, Japan)
approved the study.
VNTR proﬁling
Details of the mycobacterial genotyping methods used in the
VNTR analysis have been described previously [13]. Brieﬂy,
minisatellite loci were ampliﬁed using PCR in M. avium
respiratory isolates (i.e. from sputa or bronchial washes) of
enrolled subjects before starting the anti-mycobacterial treat-
ment. After electrophoretic separation on a 2.5% agarose gel,
the sizes of PCR amplicons were estimated using the
ChemiDoc XRS system (Bio-Rad Laboratories, Hercules,
CA, USA). The number of repeat units was determined at
16 minisatellite loci and considered to be the VNTR proﬁle of
each M. avium isolate.
Phylogenetic analysis
The genotypic diversity of M. avium clinical isolates in a
phylogenetic tree was assessed from the VNTR proﬁles, as
described previously [13]. Brieﬂy, an unrooted dendrogram
was built based on Manhattan distances between each pair of
M. avium isolates, using the neighbour-joining algorithm con-
tained in the PHYLIP software, version 3.67. Manhattan
distance was calculated by the following formula:
X16
n¼1
jAn  Bnj
where An and Bn are the number of repeat units in the nth
minisatellite locus of M. avium isolates A and B, respectively.
Principal component analysis (PCA)
To discriminate genetic groups of M. avium isolates directly
using VNTR components, PCA was used. Raw numbers of
tandem repeats at all 16 minisatellite loci for 59 M. avium
isolates were utilized to determine principal components using
the JMP Pro software, version 9.0.2 (SAS Institute, Cary, NC,
USA). Individual M. avium isolates were depicted on a scatter
plot of the two principal components that accounted for the
two greatest degrees of variance.
Statistical analysis
Normally distributed continuous data, non-normally distrib-
uted data and categorical data were evaluated between the
two study groups using Student’s t-tests, Mann–Whitney tests
and Fisher’s exact tests, respectively. Numbers of tandem
repeats at each minisatellite locus were compared between
subjects with responsive and refractory M. avium lung disease,
on the basis of a logistic regression model adjusted for age.
The result of the model was reported as an age-adjusted odds
ratio for responsive vs. refractory disease. The likelihood of
the model was examined using the chi-square test to evaluate
the null hypothesis that all variable coefﬁcients were zero (i.e.
no variables have any effect on the model). The probability of
successful treatment was calculated using the age-adjusted
multivariate logistic-regression model with VNTR proﬁle data
at MATR-2, -3, -8 and -16 loci that had been selected with the
use of a stepwise variable-selection procedure. p values of
<0.05 were considered to indicate statistical signiﬁcance. All
analyses were performed using the JMP Pro software, version
9.0.2 (SAS Institute).
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Results
Characterization of subjects
The subject group with responsive M. avium lung disease
included 10 males and 20 females with a mean age of
61  12 years at the start of treatment (Table 1). The subject
group with refractory disease included 29 persons who were
similar for age (64  11 years, p 0.41), sex (eight males and 21
females, p 0.78) and pulmonary co-morbidity (refractory
group, two subjects with chronic obstructive pulmonary
disease and one with bronchiectasis; responsive group, one
subject with lung cancer and one with bronchial asthma; p
0.67). There were no clearly signiﬁcant differences in other
radiographic and microbiological characteristics between the
responsive and refractory subjects, although subjects with
responsive disease tended to have a higher proportion of
nodular bronchiectatic features (80% vs. 76%, p 0.76), to have
fewer lung segments affected on chest computed tomography
scans (6.7 vs. 7.7, p 0.2) and to have M. avium isolates more
susceptible to clarithromycin (MIC50, 1 vs. 1 mg/L; MIC80, 2 vs.
4 mg/L; p 0.63). No clarithromycin-resistant M. avium strains
(MIC, 32 mg/L or greater [2]) were included in either subject
group. As for the treatment strategy, no signiﬁcant differences
were observed between the two groups of subjects (Table S1).
Genotyping and phylogenetic analysis of M. avium isolates
To evaluate the association of mycobacterial genotype with
therapeutic response, we obtained the VNTR proﬁling data of
all M. avium isolates, determining the numbers of tandemly
repeated motifs at minisatellite loci in the genome (Fig. 1). The
VNTR proﬁle of M. avium isolated from each subject consists
of 16 integer values from 16 minisatellite loci, MATR-1 to -16;
subjects 1–30 had responsive M. avium lung disease, while
subjects 31–59 had refractory disease. The 16 9 59 seemingly
unrelated data points permit further evaluation of the asso-
ciation between mycobacterial genotype and the clinical
response to anti-mycobacterial treatment.
When calculating genotypic diversity in the VNTR proﬁles
as the Manhattan distance between each pair of M. avium
isolates, we found phylogenetic lineages to be associated with
the therapeutic response (Fig. 2). In the phylogenetic tree,
M. avium clinical isolates were classiﬁed into three major
clusters, designated as A, B and C. The classiﬁcation yields a
nearly signiﬁcant association with the therapeutic response;
clusters A and C were more likely to include M. avium isolates
from responsive and refractory lung disease, respectively,
while cluster B did not appear to have such a propensity
(responsive/refractory disease: cluster A, 10/3; cluster B, 9/8;
cluster C, 11/18; p 0.06; Table 1). These data suggest that the
phylogenetic distribution of M. avium isolates accounts, at least
in part, for the clinical differences in the therapeutic responses
of the lung infections.
Principal component analysis (PCA) of 16-digit VNTR
proﬁling data
To conﬁrm that the diversity of mycobacterial VNTR proﬁles
reﬂected the therapeutic response, we carried out PCA using
16-digit VNTR data, without calculating Manhattan distances
(Fig. 3). Because the Manhattan distance is deﬁned as the sum
of the absolute differences in each dimension, the aggregate
measurements seem less sensitive to genetic variability. In
accordance with this view, scatter plots of principal compo-
nent (PC) 1 and PC2 from PCA of the raw VNTR data as
16-digit representation revealed that M. avium clinical isolates
were well resolved into three major groups, designated
Groups 1, 2 and 3 to avoid confusion with the clustering
shown in Fig. 2 (Fig. 3a). In this analysis, PC1 and PC2
accounted for 36% and 19.7% of the total genetic variation,
respectively, and these two components together for 55.7% of
the total variation. The amount of variation explained by PC3
was small (<8%), and therefore, additional components from
PC3 onward were disregarded.
Inspection of clinical information linked to M. avium isolates
allowed PCA to detect a correlation between the therapeutic
response and the scattering pattern of M. avium in the PCA
space (Fig. 3b). M. avium isolates from responsive lung disease
tended to form Group 1, which comprises medium PC1
scores, 0 through to 3 (19 of 30, 63.3%). In contrast, those
with refractory disease tended to form Group 2, which
comprises low PC1 scores, 4 through to 0 (18 of 29, 62.1%).
TABLE 1. Demographic and clinical characteristics of sub-
jects with Mycobacterium avium lung infection
Characteristic
Responsive
diseasea
(n = 30)
Refractory
disease
(n = 29) p
Age at start of treatmentb 61  12 64  11 0.41
Male sex, n (%) 10 (33) 8 (28) 0.78
History of lung disease, n (%) 2 (7) 3 (10) 0.67
Clinical feature, n (%) 0.76
Fibrocavitary 6 (20) 7 (24)
Nodular bronchiectatic 24 (80) 22 (76)
Affected segment, nb 6.7  3.0 7.7  3.1 0.2
Sensitivity to clarithromycinc 0.63
MIC50 (mg/L) 1 1
MIC80 (mg/L) 2 4
VNTR cluster, n (%)d 0.06
Cluster A 10 (33) 3 (10)
Cluster B 9 (30) 8 (28)
Cluster C 11 (37) 18 (62)
aResponsive disease was deﬁned as both microbiological and radiographic
improvement.
bValues represent the means  standard deviations.
cMIC50 and MIC80 refer to the minimum concentrations of clarithromycin required
to inhibit growth of 50 and 80% of M. avium isolates, respectively.
dVNTR cluster is deﬁned in Fig. 2.
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1 1 0 2 1 2 1 5 0 2 2 1 3 2 3 2 1
2 1 1 1 1 2 1 6 2 2 2 2 3 0 3 2 3
3 2 1 1 1 2 1 6 2 2 2 2 1 0 2 2 3
4 2 1 1 1 2 1 6 2 2 2 2 3 0 2 2 3
5 1 0 5 1 2 1 6 2 2 2 2 3 2 2 2 3
6 1 0 5 1 2 1 6 2 3 2 2 3 2 2 2 3
7 2 0 5 1 2 1 6 2 2 2 2 3 0 2 2 3
8 2 0 5 1 2 1 6 2 2 3 2 3 0 3 2 3
9 2 0 2 2 2 1 6 2 2 3 2 3 2 2 2 3
10 2 0 2 2 2 1 6 2 3 3 2 3 2 2 2 3
11 2 1 1 1 2 2 2 2 3 3 2 3 2 2 2 3
12 1 0 1 1 2 2 1 2 3 2 2 3 2 2 2 3
13 1 0 1 1 2 2 2 2 2 2 2 2 2 2 2 3
14 2 0 1 2 2 2 2 2 2 2 2 3 2 2 2 3
15 2 0 1 1 2 2 2 2 2 2 2 3 2 2 2 3
16 2 0 1 1 2 2 2 2 2 2 2 3 2 1 2 3
17 2 0 6 1 2 2 2 2 3 2 2 3 2 2 2 3
18 2 0 5 1 2 1 1 2 2 2 2 3 2 2 2 3
19 2 1 5 2 2 1 1 2 2 2 2 3 2 2 2 3
20 1 1 5 1 2 1 1 2 3 2 1 3 0 2 2 3
21 1 1 5 1 2 1 1 2 3 2 1 3 0 2 2 3
22 1 1 2 3 2 2 2 1 4 3 1 3 0 3 2 2
23 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
24 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
25 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
26 1 2 1 2 2 1 1 2 3 3 1 3 0 3 2 2
27 1 1 2 1 2 1 1 1 3 3 1 3 0 3 2 2
28 1 1 2 1 2 1 1 1 3 3 1 3 0 3 2 2
29 1 1 2 1 2 1 1 1 1 3 1 3 0 3 2 2
30 2 0 1 1 2 2 2 2 2 3 2 3 0 3 2 3
R
e
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ct
o
ry
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a
se
31 2 1 1 1 2 2 6 2 2 3 2 3 0 2 2 3
32 2 0 5 1 2 1 6 2 2 2 2 3 0 2 2 3
33 2 0 1 1 2 1 6 2 3 2 2 3 2 2 2 3
34 1 0 1 1 2 2 2 2 2 2 2 3 2 2 2 3
35 2 0 1 1 2 2 2 2 2 2 2 3 2 2 2 1
36 2 0 1 1 2 2 2 2 1 2 2 3 2 2 2 2
37 2 0 1 1 2 2 2 2 2 2 2 3 2 2 2 3
38 2 1 5 2 2 1 1 2 2 2 2 3 2 2 2 1
39 2 1 5 2 2 1 2 2 2 2 2 3 2 2 2 3
40 2 2 2 0 3 3 3 4 2 1 3 3 2 5 4 3
41 2 2 2 0 3 3 3 2 2 0 4 3 2 4 3 2
42 1 1 2 1 2 1 2 2 3 3 2 3 0 2 2 3
43 1 1 5 1 2 1 1 2 3 2 1 3 0 2 2 3
44 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
45 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
46 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
47 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
48 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
49 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 2
50 1 1 1 2 2 1 1 1 3 3 1 3 0 3 2 1
51 1 2 1 2 2 1 1 1 3 3 1 3 0 2 2 2
52 1 1 1 2 2 1 1 1 3 3 3 3 0 2 2 2
53 1 1 1 2 2 1 1 1 3 3 1 3 0 2 2 2
54 1 2 1 2 2 1 1 2 3 3 1 3 0 3 2 2
55 1 1 1 2 2 1 1 2 3 3 1 3 0 3 2 2
56 1 1 1 2 2 1 1 2 3 3 1 3 0 3 2 2
57 0 1 1 2 2 1 1 1 2 3 1 3 0 3 2 2
58 1 1 1 2 2 1 1 1 1 3 1 3 0 3 2 2
59 2 1 1 1 2 1 1 1 2 3 1 2 0 3 2 3
FIG. 1. VNTR proﬁles of clinical Mycobacterium avium isolates. M. avium genomic DNA was isolated from 59 subjects: subjects 1–30 with M. avium
lung disease responsive to clarithromycin-based multidrug regimens, and subjects 31–59 with lung disease refractory to treatment. The minisatellite
loci, MATR-1 to -16, were ampliﬁed from mycobacterial DNA by PCR. From the size of the PCR product, the number of repeat units in each
minisatellite locus was calculated. The numbers of tandem repeat units at 16 minisatellite loci are shown for each M. avium isolate. Boxes of the same
colour represent the same number of tandem repeats.
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Two M. avium isolates, both of which were cultured from
subjects with refractory lung disease (i.e. subjects 40 and 41),
were assigned to Group 3, deﬁned by high PC1 and PC2
scores (PC1/PC2 score: subject 40, 8/8.2; subject 41, 7/6.4).
The PCA distribution of M. avium isolates was signiﬁcantly
associated with the therapeutic response (p <0.05, Fig. 3b).
These observations support analysis of the raw 16-digit VNTR
data of M. avium to predict the therapeutic responses of lung
infections.
Prediction of the therapeutic response with VNTR data from
minimal loci
Using the raw 16-digit VNTR data of M. avium, we employed
logistic regression analysis to predict the likelihood of
successful treatment of M. avium lung infection (Table 2).
When the raw VNTR data at each minisatellite loci were
independently tested in terms of their association with
responsive M. avium lung disease, the number of repeat units
at three minisatellite loci, MATR-2, -7 and -16, showed
signiﬁcant associations in a logistic regression analysis after
adjustment for age. M. avium exhibiting fewer repeat units at
MATR-2 and more repeat units at MATR-7 and MATR-16,
were signiﬁcantly more likely to cause lung disease responsive
to anti-mycobacterial therapy (age-adjusted odds ratio for
responsive disease vs. refractory disease (95% conﬁdence
interval): MATR-2, 0.27 (0.09–0.69), p <0.05; MATR-7, 1.35
(1.02–1.87), p <0.05; MATR-16, 3.45 (1.38–9.79), p <0.05;
Table 2). Of these, two models using VNTR data at MATR-2
and MATR-16 loci were sufﬁcient to predict the probability of
successful treatment (MATR-2, v2 = 8.4, p <0.05; MATR-16,
v2 = 7.95, p <0.05; Table 2).
To improve the ability of this univariate model to estimate
the probability that patients would show a favourable response
to anti-mycobacterial medication, we conducted a multivariate
logistic regression analysis of VNTR data at minisatellite loci.
The VNTR data at 16 minisatellite loci were included in a
stepwise variable-selection analysis, and four loci, MATR-2, -3,
-8 and -16, appeared to have a cumulative association with
responsive M. avium lung disease after adjustment for age. The
ﬁnal model in which these four minisatellite loci were retained
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FIG. 2. Phylogenetic analysis of Mycobacterium avium isolates from 59
subjects with lung infections. From all VNTR proﬁle data shown in
Fig. 1, the Manhattan distance between each pair of isolates from
subjects with responsive ( ) or refractory disease ( ) was calculated.
The phylogenetic distribution was analysed by a neighbour-joining
algorithm, and is shown together with subject numbers as a radial
dendrogram. The three major branches of M. avium are designated
clusters (a), (b) and (c). The scale bar indicates genetic distance.
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FIG. 3. Genetic groups discriminated by VNTR proﬁle components.
(a) Individual Mycobacterium avium isolates represented in the principal
component analysis (PCA) space. PCA scores for numbers of tandem
repeats at 16 minisatellite loci were plotted as a scatter of M. avium
isolates from 59 subjects with responsive ( ) or refractory disease ( ).
PC1 and PC2 are the ﬁrst two principal components and explain 55.7%
of the variance (36% and 19.7% for PC1 and PC2, respectively). The
scatter plots revealed three genetic groups, which are designated
Groups 1, 2 and 3. (b). Proportions of the genetic groups among
subjects with responsive or refractory disease. p values for associa-
tions of genetic groups with therapeutic response were calculated
using Fisher’s exact test.
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remained signiﬁcant, and its proﬁciency was further improved
relative to the univariate models using MATR-2 or MATR-16
(v2 = 15.14, p <0.01). Additional adjustment for the clarithro-
mycin susceptibility resulted in a small improvement of this
multivariate model (v2 = 15.17, p 0.02).
Discussion
The present study was based on the assumption that some
mycobacterial factors of M. avium are of therapeutic relevance
in lung infections. Our data support this idea. In the study
cohort, which comprised 59 subjects with M. avium lung
infection, therapeutic response had a nearly signiﬁcant asso-
ciation with the phylogenetic distribution of the M. avium
isolates, when this was assessed by the Manhattan distance
aggregated over VNTR data from 16 minisatellite loci. The
association was further clariﬁed by applying the raw VNTR
data to principal component analysis without distance aggre-
gation. In particular, the raw VNTR data from four selected
minisatellite loci facilitated development of a signiﬁcant mul-
tivariate logistic regression model to predict the therapeutic
response.
Many questions regarding clinical management of M. avium
lung infection remain unanswered [1,2,5]. The most crucial
question that has been discussed is that of the optimal therapy
[1,2,5]. Although combination antibiotic therapy containing
clarithromycin or azithromycin offers the best chance of
treatment response, the current regimens have major limita-
tions. Even long-duration multidrug therapy, with its frequent
intolerable adverse drug reactions, leads to relatively high
failure rates, ranging from 20 to 70% [1,2,5]. Thus, many
clinicians hesitate to initiate potentially toxic treatment against
M. avium lung infection in the absence of a method of
predicting the therapeutic response. Particularly when the
disease presents in an indolent fashion, drug-related adverse
events may be more deleterious than the disease process itself.
Against this background, the present study highlights clinical
factors that enable prediction of the therapeutic response to
standard clarithromycin-containing regimens.
Although still insufﬁcient, our understanding of the patho-
physiology of M. avium lung disease has increased with regard
to both host conditions and the mycobacterial factors
emphasized in this study [1,2,5,15,16]. Five major conditions
have been recognized as predisposing host factors for
non-tuberculous mycobacterial diseases: (i) human immuno-
deﬁciency virus infection [17], (ii) genetic mutations in
signalling pathways of interferon-c and interleukin-12 [18,19],
(iii) structural lung disease such as chronic obstructive
pulmonary disease, bronchiectasis, cystic ﬁbrosis, pneumoco-
niosis, prior tuberculosis, pulmonary alveolar proteinosis and
oesophageal motility disorders [20], (iv) body morphotype,
such as scoliosis, pectus excavatum, mitral valve prolapse and
joint hypermobility [21], and (v) genetic HLA, SLC11A1
(NRAMP1), MICA and TLR2 polymorphisms [22–28]. Despite
the above, there is no clear explanation of why some
individuals, especially elderly women, become ill with poor
or good prognoses [2,29]. Recently, relevant studies have
shown that factors related to overall health status, such as
body mass index and anaemia, affect all-cause mortality of
patients with M. avium lung disease, but that the therapeutic
regimen employed as the ﬁrst line (e.g. no therapy or
combination therapy with one to ﬁve drugs) does not [30].
Thus, it seems probable that our age-adjusted model to predict
the therapeutic response of M. avium lung infection may be
further improved by considering host factors indicative of the
underlying overall health status of the patient.
Collectively, out data indicate that the therapeutic response
of M. avium lung infection is associated with mycobacterial
grouping based on VNTR. Genotypic characterization of
M. avium isolates may be a useful strategy for predicting the
clinical outcome of medication.
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TABLE 2. Age-adjusted odds ratios and 95% conﬁdence
intervals for the number of repeat units at each minisatellite
locus in subjects with responsive vs. refractory diseasea
Minisatellite
locus
Odds ratio
(95% CI)b
Chi-
square p
Model testc
Chi-square p
MATR-1 1.59 (0.59–4.42) 0.83 0.36 1.55 0.46
MATR-2 0.27 (0.09–0.69) 6.52 <0.05 8.4 <0.05
MATR-3 1.39 (1–2.02) 3.49 0.06 4.56 0.1
MATR-4 0.54 (0.21–1.33) 1.72 0.19 2.49 0.29
MATR-5 0 (0) 0 1 3.48 0.18
MATR-6 0.99 (0.37–2.68) 0 0.99 0.71 0.7
MATR-7 1.35 (1.02–1.87) 3.97 <0.05 5.17 0.08
MATR-8 1.24 (0.52–3.09) 0.23 0.63 0.95 0.62
MATR-9 0.89 (0.37–2.08) 0.07 0.79 0.79 0.68
MATR-10 0.73 (0.29–1.71) 0.51 0.47 1.24 0.54
MATR-11 1.21 (0.53–2.84) 0.21 0.65 0.92 0.63
MATR-12 0.44 (0.02–2.58) 0.62 0.43 1.47 0.48
MATR-13 1.46 (0.85–2.55) 1.82 0.18 2.58 0.27
MATR-14 0.52 (0.2–1.18) 2.19 0.14 3.12 0.21
MATR-15 0 (0) 0 1 3.48 0.18
MATR-16 3.45 (1.38–9.79) 6.24 <0.05 7.95 <0.05
aAge-adjusted odds ratios were generated using a logistic regression model.
bCI denotes conﬁdence interval.
cA chi-square test was used to examine whether the variable had an effect on the
model.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 256–262
CMI Kikuchi et al. M. avium genotype and therapeutic response 261
Open access under CC BY-NC-ND license.
of Education, Culture, Sports, Science and Technology (Tokyo,
Japan), the Core Research for Evolutional Science and
Technology Program, the Adaptable and Seamless Technology
Transfer Program from the Japan Science and Technology
Agency (Tokyo, Japan), and the Urgent Research Grant
Program from the Astellas Foundation for Research on
Metabolic Disorders (Tokyo, Japan).
Transparency Declaration
The authors declare no conﬂict of interests.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Details of the treatment for subjects with M.
avium lung infection.
References
1. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria.
Chest 2008; 133: 243–251.
2. Grifﬁth DE, Aksamit T, Brown-Elliott BA et al. An ofﬁcial ats/idsa
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416.
3. Henry MT, Inamdar L, O’Riordain D, Schweiger M, Watson JP.
Nontuberculous mycobacteria in non-hiv patients: epidemiology,
treatment and response. Eur Respir J 2004; 23: 741–746.
4. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of
pulmonary non-tuberculous mycobacteria in ontario, 1997 2003.
Thorax 2007; 62: 661–666.
5. Thomson RM, Yew WW. When and how to treat pulmonary
non-tuberculous mycobacterial diseases. Respirology 2009; 14: 12–26.
6. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance
mechanisms and drug susceptibility testing of nontuberculous myco-
bacteria. Drug Resist Updat 2012; 15: 149–161.
7. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP.
Clarithromycin vs ciproﬂoxacin as adjuncts to rifampicin and ethambutol
in treating opportunist mycobacterial lung diseases and an assessment of
mycobacterium vaccae immunotherapy. Thorax 2008; 63: 627–634.
8. Behr MA, Falkinham JO III. Molecular epidemiology of nontuberculous
mycobacteria. Future Microbiol 2009; 4: 1009–1020.
9. Neonakis IK, Gitti Z, Krambovitis E, Spandidos DA. Molecular
diagnostic tools in mycobacteriology. J Microbiol Methods 2008; 75: 1–11.
10. Oelemann MC, Diel R, Vatin V et al. Assessment of an optimized
mycobacterial interspersed repetitive-unit-variable-number tan-
dem-repeat typing system combined with spoligotyping for popula-
tion-based molecular epidemiology studies of tuberculosis. J Clin
Microbiol 2007; 45: 691–697.
11. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable
human minisatellite-like regions in the mycobacterium tuberculosis
genome. Mol Microbiol 2000; 36: 762–771.
12. Inagaki T, Nishimori K, Yagi T et al. Comparison of a variable-number
tandem-repeat (vntr) method for typing mycobacterium avium with
mycobacterial interspersed repetitive-unit-vntr and is1245 restriction
fragment length polymorphism typing. J Clin Microbiol 2009; 47: 2156–
2164.
13. Kikuchi T, Watanabe A, Gomi K et al. Association between mycobac-
terial genotypes and disease progression in mycobacterium avium
pulmonary infection. Thorax 2009; 64: 901–907.
14. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship
between clinical efﬁcacy for pulmonary mac and drug-sensitivity test
for isolated mac in a recent 6-year period. J Infect Chemother 2012; 18:
436–443.
15. Al-Houqani M, Jamieson F, Mehta M, Chedore P, May K, Marras TK.
Aging, copd, and other risk factors do not explain the increased
prevalence of pulmonary mycobacterium avium complex in ontario.
Chest 2012; 141: 190–197.
16. Ignatov D, Kondratieva E, Azhikina T, Apt A. Mycobacterium
avium-triggered diseases: pathogenomics. Cell Microbiol 2012; 14:
808–818.
17. Horsburgh CR Jr. Epidemiology of disease caused by nontuberculous
mycobacteria. Semin Respir Infect 1996; 11: 244–251.
18. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria:
the human model. Annu Rev Immunol 2002; 20: 581–620.
19. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway
defects and human disease. Cytokine Growth Factor Rev 2000; 11: 321–
333.
20. Olivier KN, Weber DJ, Wallace RJ Jr. et al. Nontuberculous myco-
bacteria. I: multicenter prevalence study in cystic ﬁbrosis. Am J Respir
Crit Care Med 2003; 167: 828–834.
21. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and
scoliosis. Thoracic anomalies associated with pulmonary disease
caused by mycobacterium avium complex. Am Rev Respir Dis 1991;
144: 914–916.
22. Koh WJ, Kwon OJ, Kim EJ, Lee KS, Ki CS, Kim JW. Nramp1 gene
polymorphism and susceptibility to nontuberculous mycobacterial lung
diseases. Chest 2005; 128: 94–101.
23. Sapkota BR, Hijikata M, Matsushita I et al. Association of slc11a1
(nramp1) polymorphisms with pulmonary mycobacterium avium com-
plex infection. Hum Immunol 2012; 73: 529–536.
24. Shojima J, Tanaka G, Keicho N et al. Identiﬁcation of mica as a
susceptibility gene for pulmonary mycobacterium avium complex
infection. J Infect Dis 2009; 199: 1707–1715.
25. Takahashi M, Ishizaka A, Nakamura H et al. Speciﬁc hla in pulmonary
mac infection in a japanese population. Am J Respir Crit Care Med 2000;
162: 316–318.
26. Tanaka G, Shojima J, Matsushita I et al. Pulmonary mycobacterium avium
complex infection: association with nramp1 polymorphisms. Eur Respir J
2007; 30: 90–96.
27. Um SW, Ki CS, Kwon OJ, Koh WJ. Hla antigens and nontuberculous
mycobacterial lung disease in korean patients. Lung 2009; 187: 136–
140.
28. Yim JJ, Kim HJ, Kwon OJ, Koh WJ. Association between microsatellite
polymorphisms in intron ii of the human toll-like receptor 2 gene and
nontuberculous mycobacterial lung disease in a korean population.
Hum Immunol 2008; 69: 572–576.
29. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare
pulmonary infection in hiv-negative patients without preexisting lung
disease: diagnostic and management limitations. Chest 1999; 115: 1033–
1040.
30. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita
Y. Prognostic factors of 634 hiv-negative patients with mycobacterium
avium complex lung disease. Am J Respir Crit Care Med 2012; 185: 575–
583.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 256–262
262 Clinical Microbiology and Infection, Volume 20 Number 3, March 2014 CMI
Open access under CC BY-NC-ND license.
